KR20220141306A - 자가면역 질환의 항-bcma 요법(anti-bcma therapy in autoimmune disorders) - Google Patents

자가면역 질환의 항-bcma 요법(anti-bcma therapy in autoimmune disorders) Download PDF

Info

Publication number
KR20220141306A
KR20220141306A KR1020227030166A KR20227030166A KR20220141306A KR 20220141306 A KR20220141306 A KR 20220141306A KR 1020227030166 A KR1020227030166 A KR 1020227030166A KR 20227030166 A KR20227030166 A KR 20227030166A KR 20220141306 A KR20220141306 A KR 20220141306A
Authority
KR
South Korea
Prior art keywords
seq
antibody
region
bcma
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227030166A
Other languages
English (en)
Korean (ko)
Inventor
코피 멘사
로버트 플렌지
소피 로이
데니스 잘러
제니퍼 도비
스티븐 샌즈
질 헤놀트
카밀 도이칸
제나 칼비노
시 진
조셉 파케트
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20220141306A publication Critical patent/KR20220141306A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227030166A 2020-02-12 2021-02-11 자가면역 질환의 항-bcma 요법(anti-bcma therapy in autoimmune disorders) Pending KR20220141306A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062975663P 2020-02-12 2020-02-12
US62/975,663 2020-02-12
PCT/US2021/017665 WO2021163329A1 (en) 2020-02-12 2021-02-11 Anti-bcma therapy in autoimmune disorders

Publications (1)

Publication Number Publication Date
KR20220141306A true KR20220141306A (ko) 2022-10-19

Family

ID=77291870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227030166A Pending KR20220141306A (ko) 2020-02-12 2021-02-11 자가면역 질환의 항-bcma 요법(anti-bcma therapy in autoimmune disorders)

Country Status (11)

Country Link
US (1) US20240052064A1 (https=)
EP (1) EP4103224A4 (https=)
JP (1) JP7783183B2 (https=)
KR (1) KR20220141306A (https=)
CN (1) CN115551539A (https=)
AU (1) AU2021221123A1 (https=)
BR (1) BR112022014646A2 (https=)
CA (1) CA3169696A1 (https=)
IL (1) IL295471A (https=)
MX (1) MX2022009784A (https=)
WO (1) WO2021163329A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
WO2023044633A1 (zh) * 2021-09-22 2023-03-30 南京驯鹿医疗技术有限公司 Bcma car-t在制备用于治疗自身免疫病的药物中的应用
WO2026033437A1 (en) * 2024-08-07 2026-02-12 Janssen Biotech, Inc. Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
WO2026037514A1 (en) * 2024-08-13 2026-02-19 Friedrich-Alexander-Universität Erlangen-Nürnberg, in Vertretung des Freistaates Bayern A bispecific binding agent targeting cd3 and bcma for the treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3331910T1 (sl) * 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
CA3287539A1 (en) * 2017-06-21 2026-03-02 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
SG11202003501XA (en) * 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen

Also Published As

Publication number Publication date
BR112022014646A2 (pt) 2022-09-13
JP2023514224A (ja) 2023-04-05
US20240052064A1 (en) 2024-02-15
EP4103224A4 (en) 2023-08-16
CN115551539A (zh) 2022-12-30
JP7783183B2 (ja) 2025-12-09
MX2022009784A (es) 2022-09-09
IL295471A (en) 2022-10-01
WO2021163329A1 (en) 2021-08-19
CA3169696A1 (en) 2021-08-19
AU2021221123A1 (en) 2022-10-06
EP4103224A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
JP7296363B2 (ja) 抗ｃｔｌａ－４抗体およびその使用
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
JP2022071087A (ja) 抗ｃｄ３８抗体および使用方法
JP7783183B2 (ja) 自己免疫障害における抗ｂｃｍａ治療
JP2025138634A (ja) Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
JP7792333B2 (ja) Ｂｃｍａおよびｃｄ３に対する抗体を用いる処置方法
CN110041429A (zh) 抗cd-3抗体，与cd3及cd20结合的双特异性抗原结合分子，及其用途
CA3106002A1 (en) Antibody molecules
CN106068275A (zh) 抗pd‑1的人抗体
JP2022517441A (ja) Ｂｔｌａ抗体
WO2021092060A1 (en) Methods of treatment
JP2021505637A (ja) 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
IL254335B (en) Isolated peptides derived from the dimerization regions of b7
EP1972640A1 (en) Apoptosis inducing antibodies
TW202220691A (zh) 用於使用ＰＤ—１ｘＣＴＬＡ—４雙特異性分子的方法
US20230172923A1 (en) Methods of treating cytokine-related adverse events
EA050324B1 (ru) Терапия антителами против bcma при аутоиммунных расстройствах
CN121712524A (zh) 包含结合bcma和cd3的抗体的组合物以及治疗方法
EA049790B1 (ru) Способы лечения антителами к bcma и cd3
KR20260057078A (ko) Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법
HK40083315A (en) Methods of treatment with antibodies against bcma and cd3
HK40092434A (zh) Btla抗体
BR122025021892A2 (pt) Células hospedeiras

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902